Galectin Therapeutics Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Hello, and welcome to the fifth annual H.C. Wainwright NASH investor conference. My name is Ed Arce; I am one of the senior biotech analysts here at H.C. Wainwright. And I am very pleased to have with us our next presenting company, Galectin Therapeutics. And representing the Company is the Chief Medical Officer, Dr. Pol Boudes. Paul, welcome to the conference.
Ed, thank you very much. Thanks for the invitation and it's always a pleasure to be here. And I already learned new things this morning, which is always very nice. You think you hear talks and -- but there is always something new going on in the world of NASH. So, that's great.
Questions & Answers
Great. I'm glad to have you with us. So let's jump right in. First question, just sort of to set the stage for perhaps those investors who may not be as familiar with the Company, is to discuss what is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |